King David R, Cohn Stephen M, Proctor Kenneth G
Dewitt-Daughtry Family Department of Surgery, Division of Trauma, Trauma and Surgical Critical Care Research Institute, University of Miami School of Medicine, Miami, Florida 33136, USA.
J Trauma. 2005 Sep;59(3):553-60; discussion 560-2.
Traumatic brain injury (TBI) remains an exclusionary criterion in nearly every clinical trial involving hemoglobin-based oxygen carriers (HBOCs) for traumatic hemorrhage. Furthermore, most HBOCs are vasoactive, and use of pressors in the setting of hemorrhagic shock is generally contraindicated. The purpose of this investigation was to test the hypothesis that low-volume resuscitation with a vasoactive HBOC (hemoglobin glutamer-200 [bovine], HBOC-301; Oxyglobin, BioPure, Inc., Cambridge, MA) would improve outcomes after severe TBI and hemorrhagic shock.
In Part 1, anesthetized swine received TBI and hemorrhage (30 +/- 2 mL/kg, n = 15). After 30 minutes, lactated Ringer's (LR) solution (n = 5), HBOC (n = 5), or 10 mL/kg of LR + HBOC (n = 5) was titrated to restore systolic blood pressure to > or = 100 mm Hg and heart rate (HR) to < or = 100 beats/min. After 60 minutes, fluid was given to maintain mean arterial pressure (MAP) at > or = 70 mm Hg and heterologous whole blood (red blood cells [RBCs], 10 mL/kg) was transfused for hemoglobin at < or = 5 g/dL. After 90 minutes, mannitol (MAN, 1 g/kg) was given for intracranial pressure > or = 20 mm Hg, LR solution was given to maintain cerebral perfusion pressure at > or = 70 mm Hg, and RBCs were given for hemoglobin of < or = 5 g/dL. In Part 2, after similar TBI and resuscitation with either LR + MAN + RBCs (n = 3) or HBOC alone (n = 3), animals underwent attempted weaning, extubation, and monitoring for 72 hours.
In Part 1, relative to resuscitation with LR + MAN + RBCs, LR + HBOC attenuated intracranial pressure (12 +/- 1 mm Hg vs. 33 +/- 6 mm Hg), improved cerebral perfusion pressure in the initial 4 hours (89 +/- 6 mm Hg vs. 60 +/- 3 mm Hg), and improved brain tissue PO2 (34.2 +/- 3.6 mm Hg vs. 16.1 +/- 1.6 mm Hg; all p < 0.05). Cerebrovascular reactivity and intracranial compliance were improved with LR + HBOC (p < 0.05) and fluid requirements were reduced (30 +/- 12 vs. 280 +/- 40 mL/kg; p < 0.05). Lactate and base excess corrected faster with LR + HBOC despite a 40% reduction in cardiac index. With HBOC alone and LR + HBOC, MAP and HR rapidly corrected and remained normal during observation; however, with HBOC alone, lactate clearance was slower and systemic oxygen extraction was transiently increased. In Part 2, resuscitation with HBOC alone allowed all animals to wean and extubate, whereas none in the LR + MAN + RBCs group was able to wean and extubate. At 72 hours, no HBOC animal had detectable neurologic deficits and all had normal hemodynamics.
The use of HBOC-301 supplemented by a crystalloid bolus was clearly superior to the standard of care (LR + MAN + RBCs) after TBI. This may represent a new indication for HBOCs. Use of HBOC eliminated the need for RBC transfusions and mannitol. The inherent vasopressor effect of HBOCs, especially when used alone, may misguide initial resuscitation, leading to transient poor global tissue perfusion despite restoration of MAP and HR. This suggests that MAP and HR are inadequate endpoints with HBOC resuscitation. HBOC use alone after TBI permitted early extubation and excellent 72-hour outcomes.
在几乎每一项涉及基于血红蛋白的氧载体(HBOCs)用于创伤性出血的临床试验中,创伤性脑损伤(TBI)仍然是一项排除标准。此外,大多数HBOCs具有血管活性,在出血性休克情况下通常禁忌使用升压药。本研究的目的是检验以下假设:使用血管活性HBOC(血红蛋白谷氨酰胺-200[牛],HBOC-301;奥克球蛋白,BioPure公司,马萨诸塞州剑桥)进行小容量复苏可改善重度TBI和出血性休克后的预后。
在第1部分中,麻醉的猪接受TBI和出血(30±2 mL/kg,n = 15)。30分钟后,滴定乳酸林格氏液(LR)(n = 5)、HBOC(n = 5)或10 mL/kg的LR + HBOC(n = 5),以将收缩压恢复至≥100 mmHg,心率(HR)恢复至≤100次/分钟。60分钟后,给予液体以维持平均动脉压(MAP)≥70 mmHg,并在血红蛋白≤5 g/dL时输注异体全血(红细胞[RBCs],10 mL/kg)。90分钟后,当颅内压≥20 mmHg时给予甘露醇(MAN,1 g/kg),给予LR溶液以维持脑灌注压≥70 mmHg,并在血红蛋白≤5 g/dL时给予RBCs。在第2部分中,在进行类似的TBI并分别用LR + MAN + RBCs(n = 3)或单独使用HBOC(n = 3)进行复苏后,对动物进行断奶、拔管尝试并监测72小时。
在第1部分中,相对于用LR + MAN + RBCs进行复苏,LR + HBOC可降低颅内压(12±1 mmHg对33±6 mmHg),在最初4小时内改善脑灌注压(89±6 mmHg对60±3 mmHg),并改善脑组织PO2(34.2±3.6 mmHg对16.1±1.6 mmHg;所有p < 0.05)。LR + HBOC可改善脑血管反应性和颅内顺应性(p < 0.05),并减少液体需求量(30±12对280±40 mL/kg;p < 0.05)。尽管心脏指数降低了40%,但LR + HBOC可使乳酸和碱剩余更快得到纠正。单独使用HBOC和LR + HBOC时,MAP和HR迅速得到纠正并在观察期间保持正常;然而,单独使用HBOC时,乳酸清除较慢,全身氧摄取短暂增加。在第2部分中,单独使用HBOC进行复苏可使所有动物断奶和拔管,而LR + MAN + RBCs组中没有动物能够断奶和拔管。在72小时时,没有HBOC组动物有可检测到的神经功能缺损,且所有动物的血流动力学均正常。
在TBI后,使用HBOC-301并辅以晶体液推注明显优于标准治疗(LR + MAN + RBCs)。这可能代表了HBOCs的一种新适应症。使用HBOC消除了输注RBCs和甘露醇的必要性。HBOCs固有的升压作用,尤其是单独使用时,可能会误导初始复苏,导致尽管MAP和HR恢复正常,但整体组织灌注暂时不佳。这表明MAP和HR作为HBOC复苏的终点是不充分的。TBI后单独使用HBOC可实现早期拔管,并在72小时时取得良好预后。